ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
2seventy bio Inc

2seventy bio Inc (TSVT)

3.61
0.45
(14.24%)
마감 25 11월 6:00AM
3.61
-0.01
(-0.28%)
시간외 거래: 8:56AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
3.61
매수가
3.57
매도가
3.94
거래량
483,252
3.16 일간 변동폭 3.7294
1.535 52주 범위 6.40
market_cap
전일 종가
3.16
개장가
3.16
최근 거래 시간
3
@
3.59
마지막 거래 시간
재정 규모
US$ 1,658,472
VWAP
3.4319
평균 볼륨(3m)
308,856
발행 주식
51,588,420
배당수익률
-
주가수익률
-0.86
주당순이익(EPS)
-4.22
매출
100.39M
순이익
-217.57M

2seventy bio Inc 정보

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker TSVT. The last closing price for 2seventy bio was US$3.16. Over the last year, 2seventy bio shares have traded in a share price range of US$ 1.535 to US$ 6.40.

2seventy bio currently has 51,588,420 shares in issue. The market capitalisation of 2seventy bio is US$163.02 million. 2seventy bio has a price to earnings ratio (PE ratio) of -0.86.

TSVT 최신 뉴스

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in...

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants...

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and...

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.35-8.838383838383.963.963.023588743.3000407CS
4-1.33-26.92307692314.945.123.023432264.32368328CS
12-1.24-25.56701030934.855.33.023088564.60658579CS
26-0.78-17.76765375854.395.33.023945444.39457292CS
521.99122.8395061731.626.41.5358983564.21561563CS
156-32.53-90.011068068636.1436.151.5358087207.96132098CS
260-22.52-86.184462303926.1344.341.5358055818.26720716CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

TSVT Discussion

게시물 보기
Monksdream Monksdream 3 월 전
TSVT under $5
👍️0
Monksdream Monksdream 7 월 전
TSVT under $5
👍️0
Invest-in-America Invest-in-America 8 월 전
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 9 월 전
TSVT 10Q due March 5
👍️0
molee molee 10 월 전
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 11 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 년 전
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 년 전
C'mon man . What the heck . $2.00 now ? Really ?
👍️0